Oct 19, 2021Libra Therapeutics Appoints Philip Lambert, Ph.D., as Chief Scientific OfficerSAN DIEGO -- Libra Therapeutics, Inc. today announced the appointment of Philip Lambert, Ph.D., as the company’s first CSO. With more...
Sep 23, 2020Libra Launches with $29M Series A to Develop Novel Therapeutics for Neurodegenerative DiseasesLibra launched with $29M to develop novel drug candidates focused on restoring the cellular balance lost in neurodegenerative diseases.
